MedTrace Logo

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

NCT06672393 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2024-11-04

No results posted yet for this study

Summary

This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

HS-10374 6mg tablets

Specified dose of HS-10374 tablets administered orally QD on specified days

DRUG

HS-10374-matched placebo tablets

Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-04
Primary Completion
2025-10-22
Completion
2026-06-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672393 on ClinicalTrials.gov